Why Tempus AI, Inc. (TEM) Stock Rose 8.7% on Nov 2, 2026
The clearest new catalyst: Earnings beat on profitability and revenue.
Why did TEM stock rise?
Tempus AI stock rose 8.7% on November 2, 2026, following the release of third-quarter earnings that beat analyst expectations on both earnings and revenue. The company reported adjusted EPS of $0.07 per share against consensus estimates of a $0.09 loss, and Q3 revenue of $411.5 million versus consensus of $409.4 million. Growth was driven by a 32% increase in oncology test volume and a 33% surge in its Data & Applications segment revenue, with Minimal Residual Disease (MRD) test volumes rising roughly 300%. Management also raised full-year 2026 revenue guidance.
- Earnings beat on profitability and revenue: Tempus AI posted adjusted EPS of $0.07 per share, vastly outperforming analyst expectations of a $0.09 per share loss, while Q3 revenue grew 23% year-over-year to $411.5 million, beating consensus estimates of $409.4 million.
- Oncology segment acceleration: Oncology test volume increased 32% and the Data & Applications segment revenue surged 33% to $108.1 million, with Minimal Residual Disease (MRD) cancer-recurrence test volumes rising approximately 300%.
- Raised full-year 2026 revenue guidance: Management increased its full-year 2026 revenue guidance, signaling confidence in sustained momentum in its core oncology diagnostics business.
Initial detection
BestStocks first flagged TEM intraday on Nov 2, 2026; this analysis was finalized after the close using the confirmed +8.7% session move and additional catalyst research.
Show the initial intraday note
Tempus AI reported third-quarter 2026 results today, with revenue from its cancer screening business rising 23% year-over-year, per Business Wire and Barron's coverage. The stock climbed 8.58% to $78.42 on elevated volume (4.63x expected at this session point), reflecting investor appetite for the company's core oncology diagnostics momentum.
What to watch next: Monitor for any follow-up guidance or management commentary on the 'major purchase' mentioned in Barron's coverage, and track whether the stock holds above $78 into the close.
Other developments that session
Tempus AI, Inc. (TEM) reported EPS of $0.07 vs. consensus estimate of −$0.09, a beat of 179.9%.
Tempus AI, Inc. (TEM) filed an 8-K on November 2, 2026. The filing details were not disclosed in available sources.
CEO Eric Lefkofsky sold 250,000 TEM shares at $70.36 each, totaling $17.59 million.
Tempus AI's cancer screening business drove Q3 revenue up 23%, beating expectations ahead of a major acquisition.
Frequently asked questions
Why did Tempus AI, Inc. (TEM) stock rise on Nov 2, 2026?
Tempus AI stock rose 8.7% on November 2, 2026, following the release of third-quarter earnings that beat analyst expectations on both earnings and revenue. The company reported adjusted EPS of $0.07 per share against consensus estimates of a $0.09 loss, and Q3 revenue of $411.5 million versus consensus of $409.4 million. Growth was driven by a 32% increase in oncology test volume and a 33% surge in its Data & Applications segment revenue, with Minimal Residual Disease (MRD) test volumes rising roughly 300%. Management also raised full-year 2026 revenue guidance.
How much did TEM stock rise on Nov 2, 2026?
TEM rose 8.7% during the Nov 2, 2026 trading session.
What were the main drivers behind TEM's move?
Earnings beat on profitability and revenue; Oncology segment acceleration; Raised full-year 2026 revenue guidance.